Skip to content

Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways

Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06971289
Acronym
DEFI
Enrollment
60
Registered
2025-05-14
Start date
2025-10-15
Completion date
2029-10-15
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoinflammatory Disease

Brief summary

Auto-inflammatory diseases are part of a heterogeneous group of illnesses manifested by an inflammatory reaction in its initial phase (innate immunity) that is activated inappropriately: either because the reaction is too strong, or because it is not justified (e.g. in the absence of infection). Autoinflammatory diseases are often initially described as genetic in origin (i.e. hereditary or familial), and preferentially affect children or young adults. However, the preponderance of auto-inflammation as a cause of symptoms has led to the development of a number of other diseases. In some cases, autoinflammatory diseases may also remain unclassified. Generally speaking, autoinflammatory diseases manifest as recurrent attacks of fever, rash and joint pain. Certain signs are more specific to certain diseases, such as urticaria, abdominal pain, mouth ulcers or cervical lymph nodes... It is above all the repetition of the attacks and their unprovoked nature that attract the attention of the patient and the doctor. These attacks are systematically associated with an increase in inflammation markers in the blood. At present, not all inflammation pathways have been identified. With this study, investigator aim to characterize rare autoinflammatory disease variants and develop relevant cellular models to study inflammation pathways.

Interventions

OTHERblood test

blood test as part of routine care

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No

Inclusion criteria

For adults : Inclusion Criteria : * Major patient * Patient with a rare autoinflammatory disease * Patient who has given his or her consent to participate in research

Exclusion criteria

: * Patient under legal protection or safeguard of justice or any other protective measure (guardianship, curatorship) * Patient with known infection with hepatitis B or C virus or human immunodeficiency virus (HIV) For Kids : Inclusion Criteria : * Minor patients (between 4 and 17 years of age) * Patient with a rare autoinflammatory disease. * No additional genetic research will be carried out as part of the project. * Parents/legal guardians of the child who have given their non-objection to participate in the research.

Design outcomes

Primary

MeasureTime frameDescription
The main judgment criterion will be analysis of the Cytokine/chemokine release assays.At inclusion Day 0Comparison of pro- and anti-inflammatory cytokine concentrations (IL-8, TNF (Tumor Necrosis Factor), chemokine CC ligand 3 and 4 concentrations (CCL3, CCL4) by ELISA in cells supernatants according to the inflammatory pathway involved.

Contacts

Primary ContactYvan Jamilloux, MD
Yvan.jamilloux@chu-lyon.fr04.26.73.26.36
Backup ContactNora Martel
nora.martel@chu-lyon.fr04 72 07 13 40

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026